Evidence map›Paper›PMID 38758559›Full record

ArticleJAMA network open2024

Travel-Time Disparities in Access to Proton Beam Therapy for Cancer Treatment.

Todd Burus, Alexander D VanHelene, Michael K Rooney, Krystle A Lang Kuhs, W Jay Christian, Christopher McNair, Sanjay Mishra, Arnold C Paulino, Grace L Smith, Steven J Frank and 1 more

Abstract read
In one paragraph

Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Proton Therapy Utilization Among Adult Cancer Patients.International journal of particle therapy · 2026
    Article
  3. Comparative outcomes of proton and photon therapy in the management of malignant peripheral nerve sheath tumors.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Todd BurusMarkey Cancer Center, University of Kentucky, Lexington.
Alexander D VanHeleneLifespan Cancer Institute, Rhode Island Hospital, Providence.
Michael K RooneyDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston.
Krystle A Lang KuhsMarkey Cancer Center, University of Kentucky, Lexington.
W Jay ChristianDepartment of Epidemiology & Environmental Health, College of Public Health, University of Kentucky, Lexington.
Christopher McNairDepartment of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Sanjay MishraLifespan Cancer Institute, Rhode Island Hospital, Providence.
Arnold C PaulinoDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston.
Grace L SmithDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston.
Steven J FrankDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston.
Jeremy L WarnerLifespan Cancer Institute, Rhode Island Hospital, Providence.

Funding

Enhancing the HemOnc Knowledgebase of Chemotherapy Drugs and RegimensU24CA265879 · NCI · RHODE ISLAND HOSPITAL · PI Jeremy L Warner · 2022 to 2026
$3.4M
NCI NIH HHS U24 CA265879
6 · The paper itself

Abstract

Importance: Proton beam therapy is an emerging radiotherapy treatment for patients with cancer that may produce similar outcomes as traditional photon-based therapy for many cancers while delivering lower amounts of toxic radiation to surrounding tissue. Geographic proximity to a proton facility is a critical component of ensuring equitable access both for indicated diagnoses and ongoing clinical trials. Objective: To characterize the distribution of proton facilities in the US, quantify drive-time access for the population, and investigate the likelihood of long commutes for certain population subgroups. Design, Setting, and Participants: This population-based cross-sectional study analyzed travel times to proton facilities in the US. Census tract variables in the contiguous US were measured between January 1, 2017, and December 31, 2021. Statistical analysis was performed from September to November 2023. Exposures: Drive time in minutes to nearest proton facility. Population totals and prevalence of specific factors measured from the American Community Survey: age; race and ethnicity; insurance, disability, and income status; vehicle availability; broadband access; and urbanicity. Main Outcomes and Measures: Poor access to proton facilities was defined as having a drive-time commute of at least 4 hours to the nearest location. Median drive time and percentage of population with poor access were calculated for the entire population and by population subgroups. Univariable and multivariable odds of poor access were also calculated for certain population subgroups. Results: Geographic access was considered for 327 536 032 residents of the contiguous US (60 594 624 [18.5%] Hispanic, 17 974 186 [5.5%] non-Hispanic Asian, 40 146 994 [12.3%] non-Hispanic Black, and 195 265 639 [59.6%] non-Hispanic White; 282 031 819 [86.1%] resided in urban counties). The median (IQR) drive time to the nearest proton facility was 96.1 (39.6-195.3) minutes; 119.8 million US residents (36.6%) lived within a 1-hour drive of the nearest proton facility, and 53.6 million (16.4%) required a commute of at least 4 hours. Persons identifying as non-Hispanic White had the longest median (IQR) commute time at 109.8 (48.0-197.6) minutes. Multivariable analysis identified rurality (odds ratio [OR], 2.45 [95% CI, 2.27-2.64]), age 65 years or older (OR, 1.09 [95% CI, 1.06-1.11]), and living below the federal poverty line (OR, 1.22 [1.20-1.25]) as factors associated with commute times of at least 4 hours. Conclusions and Relevance: This cross-sectional study of drive-time access to proton beam therapy found that disparities in access existed among certain populations in the US. These results suggest that such disparities present a barrier to an emerging technology in cancer treatment and inhibit equitable access to ongoing clinical trials.

Indexed as

Healthcare DisparitiesHealth Services AccessibilityNeoplasmsProton TherapyTravelAdultAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedTime FactorsUnited States

Identifiers

PMID38758559
PMCPMC11102024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.